Private Wealth Asset Management LLC Sells 491 Shares of Pfizer Inc. $PFE

Private Wealth Asset Management LLC lowered its holdings in Pfizer Inc. (NYSE:PFE) by 1.5% during the 2nd quarter, Holdings Channel reports. The firm owned 33,207 shares of the biopharmaceutical company’s stock after selling 491 shares during the period. Private Wealth Asset Management LLC’s holdings in Pfizer were worth $805,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also bought and sold shares of the business. Mitchell Mcleod Pugh & Williams Inc. boosted its position in Pfizer by 22.8% in the second quarter. Mitchell Mcleod Pugh & Williams Inc. now owns 42,316 shares of the biopharmaceutical company’s stock worth $1,026,000 after purchasing an additional 7,859 shares during the last quarter. JGP Wealth Management LLC boosted its position in Pfizer by 5.4% in the second quarter. JGP Wealth Management LLC now owns 23,430 shares of the biopharmaceutical company’s stock worth $568,000 after purchasing an additional 1,193 shares during the last quarter. Cypress Wealth Services LLC boosted its position in Pfizer by 4.1% in the second quarter. Cypress Wealth Services LLC now owns 18,444 shares of the biopharmaceutical company’s stock worth $447,000 after purchasing an additional 719 shares during the last quarter. Bayforest Capital Ltd boosted its position in Pfizer by 172.2% in the second quarter. Bayforest Capital Ltd now owns 3,005 shares of the biopharmaceutical company’s stock worth $73,000 after purchasing an additional 1,901 shares during the last quarter. Finally, Sagespring Wealth Partners LLC boosted its position in Pfizer by 21.7% in the second quarter. Sagespring Wealth Partners LLC now owns 53,990 shares of the biopharmaceutical company’s stock worth $1,309,000 after purchasing an additional 9,610 shares during the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Analyst Ratings Changes

PFE has been the topic of several research analyst reports. UBS Group reissued a “neutral” rating and issued a $28.00 price objective on shares of Pfizer in a research report on Wednesday, October 1st. Citigroup upped their price target on Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a research report on Wednesday, August 6th. Bank of America upped their price target on Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a research report on Friday, October 3rd. Morgan Stanley dropped their price target on Pfizer from $33.00 to $32.00 and set an “equal weight” rating on the stock in a research report on Friday. Finally, Wall Street Zen cut Pfizer from a “buy” rating to a “hold” rating in a research report on Sunday, September 28th. Two analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, twelve have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $28.35.

Pfizer Stock Performance

NYSE:PFE opened at $24.53 on Wednesday. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $29.82. The firm has a market cap of $139.44 billion, a price-to-earnings ratio of 13.05, a PEG ratio of 0.82 and a beta of 0.55. The business’s fifty day moving average is $24.88 and its 200 day moving average is $24.12.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.58 by $0.20. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The company had revenue of $14.65 billion for the quarter, compared to analyst estimates of $13.43 billion. During the same period in the previous year, the company posted $0.60 EPS. The firm’s revenue for the quarter was up 10.3% compared to the same quarter last year. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Research analysts predict that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 1st. Investors of record on Friday, November 7th will be paid a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.0%. The ex-dividend date is Friday, November 7th. Pfizer’s payout ratio is presently 91.49%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.